↓ Skip to main content

Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure

Overview of attention for article published in BMC Infectious Diseases, May 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure
Published in
BMC Infectious Diseases, May 2016
DOI 10.1186/s12879-016-1545-8
Pubmed ID
Authors

Jose Ángel Fernández-Caballero, Natalia Chueca, Marta Álvarez, María Dolores Mérida, Josefa López, José Antonio Sánchez, David Vinuesa, María Ángeles Martínez, José Hernández, Federico García

Abstract

In our study, we have hypothesized that proviral DNA may show the history of mutations that emerged at previous failures to a Raltegravir containing regimen, in patients who are currently undetectable and candidates to simplification to a Dolutegravir containing regimen, in order to decide on once a day or twice a day dosing. We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1, all with a history of previous failure to a RAL containing regimen, that were successfully salvaged and had reached viral suppression. A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. After an average (IQR) time of 48 months (29-53) Integrase resistance mutations in proviral DNA were studied. All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain, and 4 were women. Median viral load (log) and CD4 count at the moment of the study on proviral DNA was of 1.3 log cp/ml (range 0-1.47) and 765.5 cells/μL (range; 436.75-1023.75). The median time (IQR) between previous failure to RAL and the study on proviral DNA was 48 (29-53) months. At Raltegravir failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %). In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient. Sanger sequencing correctly identified all the secondary mutations. This is a pilot study that demonstrates the possibility of properly identifying N155H and some secondary mutations 29-53 months after failure.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 1 3%
Argentina 1 3%
Unknown 29 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 16%
Student > Bachelor 4 13%
Researcher 3 10%
Professor > Associate Professor 3 10%
Professor 2 6%
Other 9 29%
Unknown 5 16%
Readers by discipline Count As %
Medicine and Dentistry 14 45%
Agricultural and Biological Sciences 2 6%
Immunology and Microbiology 2 6%
Biochemistry, Genetics and Molecular Biology 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 4 13%
Unknown 7 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2017.
All research outputs
#6,005,717
of 11,389,380 outputs
Outputs from BMC Infectious Diseases
#1,514
of 4,231 outputs
Outputs of similar age
#108,955
of 278,504 outputs
Outputs of similar age from BMC Infectious Diseases
#55
of 155 outputs
Altmetric has tracked 11,389,380 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,231 research outputs from this source. They receive a mean Attention Score of 4.1. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,504 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 155 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.